Amgen enlists Orion for Finnish Amgevita
Executive Summary
Amgen and Orion have struck a sales and marketing collaboration for the US firm’sAmgevita (adalimumab) biosimilar in Finland. The deal for “Finland’s first adalimumab biosimilar” comes as Amgen competes with Biogen, Mylan and Sandoz to take market share in Europe away from AbbVie’s Humira reference brand after the arthritis blockbuster lost its supplementary protection certificate (SPC) monopoly in mid- October (Generics bulletin, 26 October 2018, page 1).